Records containing: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-10Content, Semantic, and Psychometric Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
-
CLINICAL_TRIALS study record update · 2025-12-15Incorporating the Venous Excess Ultrasound Score (VExUS Score) Into Contemporary Haemodynamic Risk Assessment in Pulmonary Arterial Hypertension: The INVEXUS-PAH Study
-
CLINICAL_TRIALS study record update · 2025-11-18The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
-
CLINICAL_TRIALS study record update · 2025-11-03Rutgers University Study of the Genetics of Pulmonary Hypertension
-
CLINICAL_TRIALS study record update · 2025-10-01ACTION - The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-09-30PANDORA: PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
-
CLINICAL_TRIALS study record update · 2025-06-13A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-001Pro in Pulmonary Arterial Hypertension
-
CLINICAL_TRIALS study record update · 2025-06-10imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Multicenter Pre- and Post-intervention Evaluation Study
-
CLINICAL_TRIALS study record update · 2023-11-13Prospective, Multi-center, Double-blind, Randomized, Active-controlled, Triple-dummy, Parallel-group, Group-sequential, Adaptive Phase 3 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed Dose Combination in Subjects With Pulmonary Arterial Hypertension (PAH), Followed by an Open-label Treatment Period With Macitentan and Tadalafil Fixed Dose Combination Therapy